Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2017

  • ID: 4426930
  • Report
  • 115 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2017

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 3, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal and Central Nervous System which include indications Hepatocellular Carcinoma, Solid Tumor, Type 2 Diabetes, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Biliary Tract Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • H3 Biomedicine Inc
  • Ionis Pharmaceuticals Inc
  • MORE
Introduction

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Amgen Inc

ArQule Inc

AstraZeneca Plc

Blueprint Medicines Corp

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Genosco Inc

H3 Biomedicine Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

Merrimack Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Novartis AG

Principia Biopharma Inc

Tasly Pharmaceutical Group Co Ltd

Vichem Chemie Research Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles

ARQ-087 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-709 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-9931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FGF-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golvatinib tartrate + lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-62079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infigratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-463588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2874455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSLB-1344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China

Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017

Oct 19, 2017: NGM Bio Provides Update On NGM282 In NASH

Oct 10, 2017: H3 Biomedicine Granted Orphan Drug Designation of H3B-6527 for Treatment of Hepatocellular Carcinoma

Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting

Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA

Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer

Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference

Sep 15, 2017: H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting

Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress

Sep 11, 2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress

Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma

Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress

Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress

Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Amgen Inc, H2 2017

Pipeline by ArQule Inc, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Blueprint Medicines Corp, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by Eisai Co Ltd, H2 2017

Pipeline by Eli Lilly and Co, H2 2017

Pipeline by Genosco Inc, H2 2017

Pipeline by H3 Biomedicine Inc, H2 2017

Pipeline by Incyte Corp, H2 2017

Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Pipeline by Johnson & Johnson, H2 2017

Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Pipeline by NGM Biopharmaceuticals Inc, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Principia Biopharma Inc, H2 2017

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Pipeline by Vichem Chemie Research Ltd, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • ArQule Inc
  • AstraZeneca Plc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Genosco Inc
  • H3 Biomedicine Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • Johnson & Johnson
  • Merrimack Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Principia Biopharma Inc
  • Tasly Pharmaceutical Group Co Ltd
  • Vichem Chemie Research Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll